Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alder BioPharmaceuticals Inc.

Division of Alder Biopharmaceuticals Inc.
www.alderbio.com

Latest From Alder BioPharmaceuticals Inc.

Novartis Gets NICE Headache From Aimovig Knockback

The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.

Reimbursement Neurology

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches

CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.

Launches Sales & Earnings

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.

Pricing Strategies Reimbursement

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.

Approvals Launches
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alder Biopharmaceuticals Inc.
  • Senior Management
  • Robert W Azelby, CEO
    Carlos Campoy, CFO
    Mark J Litton, PhD, CBO
    John A Latham, PhD, CSO
    Elisabeth A Sandoval, Chief Commercial Officer & EVP, Corp. Strat.
    Erin Lavelle, COO
  • Contact Info
  • Alder BioPharmaceuticals Inc.
    Phone: (425) 205-2900
    11804 North Creek Pkwy. S.
    Bothell, WA 98011
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register